Send us Fan Mail

Send us Fan Mail

PSMA Lutetium has been in the background for metastatic prostate cancer for several years.

Joins us as we discuss this exciting treatment in metastatic prostate cancer with the excellent Dr Amy Eccles who works at Imperial Hospital London and also the London Clinic. Amy is a radiologist who delivers PSMA Lutetium at the London Clinic and shares her experience with us.

Attaching Lutetium-177 to PSMA to deliver a beta-emitting radiation payload to prostate cancer cells. Essentially targeted liquid radiotherapy.

This is novel therapy that is not yet funded in the NHS.

We discuss who a good patient may be and what potential side effects they could expect.

This field of Theranostics is expending rapidly and where does this sit with our current prostate cancer treatment landscape??

Send a text

Late effects after pelvic radiotherapy part 2.

Join us as we complete our conversation with the wonderful Macmillan Late effects consultant radiographer Lisa Durrant.

Last week we discussed late bladder and bowel effects from radiotherapy.

In this weeks episode we discuss;

- hyperbaric oxygen therapy

- pelvic floor exercises

- pain as a late effect of radiotherapy

- sexual function issues post radiotherapy

Lisa gives us some great practical tips on how to support patients after their radiotherapy along the way.

Enjoy!

For more info on pelvic radiation disease and late effects from pelvic radiation check out www.prda.org.uk

Send a text

Join us as we discuss the impact of Pelvic Radiation Disease & the late effects of radiotherapy in the pelvis.

We re always trying to get he best result for our patients and to cure cancer but we need to take time to deal with the impact of radiotherapy side effects in our patients.

We are talking radiotherapy for pelvic cancers; bladder, prostate, gynaecological and rectal cancers.
Lisa is a consultant radiographer pioneering support for patients with late effects of radiotherapy. She leads her radiotherapy late effects service at Musgrove Park hospital in Taunton.

In this first of 2 parts we discuss;
🔎 What is Pelvic radiation Disease
🔎 When are effects 'Late Effects' from radiotherapy
🔎 Strategies for dealing with bladder and bowel side effects

A must listen for anyone who is delivering pelvic radiotherapy and a useful tool for patients receiving radiotherapy to the pelvis.

Enjoy!!

Send a text

Join us as return to our excellent conversation on biomarkers in kidney cancer with the wonderful Professor Laurence Albiges from Paris.

🎙️We finish our overview of Biomarkers in metastatic Kidney Cancer with the superb Professor Laurence Albiges from the Gustave Roussy Hospital in Paris 🇫🇷

Which biomarker will help us to decide which treatment to select in metastatic #KidneyCancer
- IOIO vs IOTKi
- when to start therapy
- monitoring on treatment

An exciting space and none better than Laurence to walk us through it.

💊KIM 1
💊 CtDNA
💊Microbiome
💊PDL1
💊NLR

Which will be our winner in 2026⭐️

🇫🇷Also with 2 minute summary in French for anyone wanting an oncology version of Duolingo 🇫🇷

Send a text

Join us for a special Kidney Cancer treat!!!

A Must Listen episode!!

We discuss the role of biomarkers in advanced kidney cancer with the wonderful Professor Laurence Albiges from the Gustave Roussy Institute of Oncology in Paris.

No Kidney Cancer talk is complete without the question -" Where are we with biomarkers?"

This is part 1 of a 2 part walkthrough of the biomarker story so far in kidney cancer.

Laurence is unequalled in her clear delivery on this subject.

As lead for the CARE-1 study Laurence is examining the role of PDL1 as a biomarker in 1st line treatment of mRCC.

We also discuss the;

- IMDC criteria

- Clusters

- KIM-1

- PDL1

- Sarcomatoid features

Recorded before Christmas this is a gift that keeps on giving.

We hope you enjoy!!

Check the Transcript for more details.

Send a text

Join us as we return to complete our run through the landscape of metastatic renal cancer with the effervescent Professor Ricky Frazer.

We look at the Dolly Mixture of subtypes that makes up non clear cell renal carcinoma.

We discuss the new HIF2a inhibitors such as belzutifan.

We look at future directions in kidney cancer.

A treat for anyone who treats kidney cancer.

Enjoy!

Send a text

Join us is as we celebrate Kidney Cancer week with a Masterclass walk through metastatic Renal Cancer with Professor Ricky Frazer from Velindre Cancer Centre.

Ricky is a co-host of the hugely successful Immunobuddies podcast and has a vast experience in immunotherapy management.

We look at the indications for immunotherapy versus anti-VEGF TKI therapy.

Should we just accept anti-VEGF TKI monotherapy in Favourable Risk patients?

When should we try IO/IO combination versus IO/TKI combinations in the first line setting?

All this whilst Ricky looks to put John in his place!!

Enjoy